Cargando…

SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals

Immune responses at the respiratory mucosal interface are critical to prevent respiratory infections but it is unclear to what extent antigen specific mucosal secretory IgA (SIgA) antibodies are induced by mRNA vaccination in humans. Here we analyze paired serum and saliva samples from patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sano, Kaori, Bhavsar, Disha, Singh, Gagandeep, Floda, Daniel, Srivastava, Komal, Gleason, Charles, Carreño, Juan Manuel, Simon, Viviana, Krammer, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9435409/ https://www.ncbi.nlm.nih.gov/pubmed/36050304 http://dx.doi.org/10.1038/s41467-022-32389-8

Ejemplares similares

SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants
por: Kubale, John, et al.
Publicado: (2022)

Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections
por: Singh, Gagandeep, et al.
Publicado: (2023)

Detection of SARS-CoV-2 Antibodies in Immunoglobulin Products
por: Cousins, Kimberley, et al.
Publicado: (2023)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations
por: Carreño, Juan Manuel, et al.
Publicado: (2022)

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
por: Ju, Yi, et al.
Publicado: (2022)

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
por: Krammer, Florian, et al.
Publicado: (2021)

Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants
por: Gonzalez-Reiche, Ana S., et al.
Publicado: (2023)

Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies
por: Kirkpatrick Roubidoux, Ericka, et al.
Publicado: (2022)

Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2
por: Williams, Erin, et al.
Publicado: (2022)

Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination
por: Amanat, Fatima, et al.
Publicado: (2023)

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
por: Van Oekelen, Oliver, et al.
Publicado: (2021)

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals
por: Longet, Stephanie, et al.
Publicado: (2022)

Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
por: Carreño, Juan Manuel, et al.
Publicado: (2021)

Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms
por: Carreño, Juan Manuel, et al.
Publicado: (2021)

Monoclonal antibodies targeting the influenza virus N6 neuraminidase
por: Strohmeier, Shirin, et al.
Publicado: (2022)

Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain
por: Altomare, Clara G., et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
por: Amanat, Fatima, et al.
Publicado: (2021)

Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase
por: Kirkpatrick Roubidoux, Ericka, et al.
Publicado: (2021)

SARS-CoV-2 Specific IgG Antibodies Persist Over a 12-Month Period in Oral Mucosal Fluid Collected From Previously Infected Individuals
por: Chellamuthu, Prithivi, et al.
Publicado: (2021)

The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
por: Amanat, Fatima, et al.
Publicado: (2021)

Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination
por: Kogan Zajdman, Ariel, et al.
Publicado: (2022)

OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment
por: Oekelen, Oliver Van, et al.
Publicado: (2021)

Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
por: Muena, Nicolás A., et al.
Publicado: (2022)

Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2
por: Raiden, Silvina, et al.
Publicado: (2021)

SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup
por: Stadlbauer, Daniel, et al.
Publicado: (2020)

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
por: Aleman, Adolfo, et al.
Publicado: (2022)

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
por: Aleman, Adolfo, et al.
Publicado: (2021)

NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine
por: Verina, Daniel, et al.
Publicado: (2021)

Detection of Antibody Responses against SARS-CoV-2 in Plasma and Saliva from Vaccinated and Infected Individuals
por: Klingler, Jéromine, et al.
Publicado: (2021)

Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals
por: Klingler, Jéromine, et al.
Publicado: (2021)

Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats
por: Tcheou, Johnstone, et al.
Publicado: (2021)

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
por: Manisty, Charlotte, et al.
Publicado: (2021)

Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

Longer Intervals before Vaccination Increase Spike Antibody Titers in Individuals Previously Infected with SARS-CoV-2
por: Bi, Xiuqiong, et al.
Publicado: (2022)

Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants
por: Changrob, Siriruk, et al.
Publicado: (2023)

Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control
por: Werzberger, Alan, et al.
Publicado: (2021)

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer
por: Mack, Philip C., et al.
Publicado: (2022)

Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
por: González-Domínguez, Irene, et al.
Publicado: (2022)

Bacteriocin production by mucosal bacteria in current and previous colorectal neoplasia
por: Kohoutova, Darina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sp9s165ehtlc7bk20o1jdmu4em